Getting Syk: Spleen tyrosine kinase as a therapeutic target

Trends in Pharmacological Sciences

Volumn 35, Issue 8, 2014, Pages 414-422

  Geahlen, Robert L ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

allergic asthma; fostamatinib; leukemia; protein kinase inhibitor; rheumatoid arthritis; tyrosine phosphorylation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FC RECEPTOR; FOSTAMATINIB; HEPARIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; P 50515; PICEATANNOL; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 112; R 343; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BINDING AFFINITY; CANCER CELL; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG STRUCTURE; DRUG TARGETING; FOLLICULAR LYMPHOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSULIN DEPENDENT DIABETES MELLITUS; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MANTLE CELL LYMPHOMA; MAST CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BINDING; REPERFUSION INJURY; RETINOBLASTOMA; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ALLERGIC ASTHMA; FOSTAMATINIB; LEUKEMIA; PROTEIN KINASE INHIBITOR; RHEUMATOID ARTHRITIS; TYROSINE PHOSPHORYLATION;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84905459655     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.05.007     Document Type: Review

References (108)

1. L. Xue et al. Identification of direct kinase substrates based on protein kinase assay-linked phosphoproteomics Mol. Cell. Proteomics 12 2013 2969 2980
2. B. Heizmann et al. Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor Proc. Natl. Acad. Sci. U.S.A. 107 2010 18563 18568
3. F.M. Uckun et al. Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros Proc. Natl. Acad. Sci. U.S.A. 109 2012 18072 18077
4. R.L. Geahlen Syk and pTyr'd: signaling through the B cell antigen receptor Biochim. Biophys. Acta 1793 2009 1115 1127
5. A. Mócsai et al. The SYK tyrosine kinase: a crucial player in diverse biological functions Nat. Rev. Immunol. 10 2010 387 402
6. S. Deindl et al. Structural basis for the inhibition of tyrosine kinase activity of ZAP-70 Cell 129 2007 735 746
7. U. Grädler et al. Structural and biophysical characterization of the Syk activation switch J. Mol. Biol. 425 2013 309 333
8. B.A. Liu et al. The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling Mol. Cell 22 2006 851 868
9. K. Fütterer et al. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide J. Mol. Biol. 281 1998 523 537
10. C.L. Abram, and C.A. Lowell The expanding role for ITAM-based signaling pathways in immune cells Sci. STKE 2007 2007 re2
11. D. Yablonski, and A. Weiss Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart BLNK/SLP-65 Adv. Immunol. 79 2001 93 128
12. L.B. Ivashkiv Cross-regulation of signaling by ITAM-associated receptors Nat. Immunol. 10 2009 340 347
13. H.J. Gould, and B.J. Sutton IgE in allergy and asthma today Nat. Rev. Immunol. 8 2008 205 217
14. M.D. Holdon et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI Nat. Struct. Mol. Biol. 18 2011 571 576
15. L.E. Cheng et al. Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E Immunity 38 2013 166 175
16. A.M. Gilfillan, and J. Rivera The tyrosine kinase network regulating mast cell activation Immunol. Rev. 228 2009 149 169
17. P.S. Costello et al. Critical role for the tyrosine kinase Syk in signaling through the high affinity IgE receptor of mast cells Oncogene 13 1996 2595 2605
18. M. Simon et al. Distinct roles for the linker region tyrosines of Syk in FcεRI signaling in primary mast cells J. Biol. Chem. 280 2004 4510 4517
19. E. Wex et al. Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo Eur. J. Immunol. 41 2011 3208 3218
20. P.J. Barnes Immunology of asthma and chronic obstructive pulmonary disease Nat. Rev. Immunol. 8 2008 183 192
21. L. Cohn et al. Asthma: mechanisms of disease persistence and progression Ann. Rev. Immunol. 22 2004 789 815
22. L.C. Wu Immunoglobulin E receptor signaling and asthma J. Biol. Chem. 286 2011 32891 32897
23. M. Kaur et al. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review Eur. J. Med. Chem. 67 2013 434 446
24. W.S.F. Wong, and K.P. Leong Tyrosine kinase inhibitors: a new approach for asthma Biochim. Biophys. Acta 1697 2004 53 69
25. P.C. Penton et al. Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma J. Allergy Clin. Immun. 131 2013 512 520
26. N. Yamamoto et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4- dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents J. Pharmacol. Exp. Ther. 306 2003 1174 1181
27. C.J. Seow et al. Piceatannol a Syk-selective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro Eur. J. Pharmacol. 443 2002 189 196
28. G.R. Stenton et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase J. Immunol. 169 2002 1028 1036
29. Z-Y. Huang et al. Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma Mol. Immunol. 53 2013 52 59
30. E.O. Meltzer et al. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment J. Allergy Clin. Immunol. 115 2005 791 796
31. G. Sanchez-Mejorada, and C. Rosales Signal transduction by immunoglobulin Fc receptors J. Leukoc. Biol. 63 1998 521 533
32. J.A. Van Ziffle, and C.A. Lowell Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection Blood 114 2009 4871 4882
33. F. Kiefer et al. The Syk protein tyrosine kinase is essential for Fcγ receptor signaling in macrophages and neutrophils Mol. Cell. Biol. 18 1998 4209 4220
34. A. Mócsai et al. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs Nat. Immunol. 7 2006 1326 1333
35. S. Kleinau et al. Induction and suppression of collagen-induced arthritis is dependent on distinct Fcgamma receptors J. Exp. Med. 191 2000 1611 1616
36. T. Díaz de Ståhl et al. Expression of FcgammaRIII is required for development of collagen-induced arthritis Eur. J. Immunol. 32 2002 2915 2922
37. Z. Jakus et al. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis Arthritis Rheum. 62 2010 1899 1910
38. E.R. Elliott et al. Deletion of Syk in neutrophils prevents immune complex arthritis J. Immunol. 187 2011 4319 4330
39. M. Bajpai et al. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis Expert Opin. Investig. Drugs 17 2008 641 659
40. S. Braselmann et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation J. Pharmacol. Exp. Ther. 319 2006 998 1008
41. P.R. Pine et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor Clin. Immunol. 124 2007 244 257
42. G. Coffey et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis J. Pharmacol. Exp. Ther. 340 2012 350 359
43. J. Liddle et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor Bioorg. Med. Chem. Lett. 21 2011 6188 6194
44. C. Liao et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy Arthritis Res. Ther. 15 2013 R146
45. M.E. Weinblatt et al. Treatment of rheumatoid arthritis with a Syk inhibitor: a twelve week, randomized, placebo-controlled trial Arthritis Rheum. 58 2008 3309 3318
46. M.E. Weinblatt et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis N. Engl. J. Med. 363 2010 1303 1312
47. M.C. Genovese et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three month randomized, placebo controlled phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents Arthritis Rheum. 63 2011 337 345
48. A. Mócsai et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase Proc. Natl. Acad. Sci. U.S.A. 101 2004 6158 6163
49. H. Cha et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes J. Pharmacol. Exp. Ther. 317 2006 571 578
50. J-C. Gevrey et al. Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (fractalkine) J. Immunol. 175 2005 3737 3745
51. A. Zarbock et al. PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling J. Exp. Med. 205 2008 2339 2347
52. I. Hilgendorf et al. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice Arterioscler. Thromb. Vasc. Biol. 31 2011 1991 1999
53. S.N. Liossis et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events J. Clin. Invest. 98 1996 2549 2557
54. V.R. Moulton, and G.C. Tsokos Abnormalities of T cell signaling in systemic lupus erythematosus Arthritis Res. Ther. 13 2011 207
55. M. Turner et al. Perinatal lethality and a block in the development of B cells in mice lacking the tyrosine kinase p72syk Nature 378 1995 298 302
56. 2+ mobilization through distinct pathways EMBO J. 13 1994 1341 1349
57. S.N. Liossis et al. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus J. Investig. Med. 49 2001 157 165
58. C. Lamagna et al. B cell-specific loss of Lyn kinase leads to autoimmunity J. Immunol. 192 2014 919 928
59. J.E. Smith-Garvin et al. T Cell Activation Ann. Rev. Immunol. 27 2009 591 619
60. A.P. Grammatikos et al. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling PLoS ONE 8 2013 e74550
61. F.R. Bahjat et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus Arthritis Rheum. 58 2008 1433 1444
62. G.M. Deng et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice Arthritis Rheum. 62 2010 2086 2092
63. J. Smith et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis J. Am. Soc. Nephrol. 21 2010 231 236
64. M.P. Reilly et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model Blood 117 2011 2241 2246
65. A. Podolanczuk et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk Blood 113 2009 3154 3160
66. C. Sedlik et al. A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation J. Immunol. 170 2003 846 852
67. L. Colonna et al. Therapeutic targeting of Syk in autoimmune diabetes J. Immunol. 185 2010 1532 1543
68. D.L. Carden, and D.N. Granger Pathophysiology of ischaemia-reperfusion injury J. Pathol. 190 2000 255 266
69. O.N. Pamuk et al. Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion Am. J. Physiol. Gastrointest. Liver Physiol. 299 2010 G391 G399
70. Y. Shi et al. Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis Blood 107 2005 4554 4562
71. F. Ishizuka et al. Toll-like receptor 4 mediates retinal ischemia/reperfusion injury through nuclear factor-κB and spleen tyrosine kinase activation Invest. Opththalmol. Vis. Sci. 54 2013 5807 5816
72. A. Chaudhary Tyrosine kinase Syk associates with toll-like receptor 4 and regulates signaling in human monocytic cells Immunol. Cell Biol. 85 2007 249 256
73. Y.I. Miller et al. The SYK side of TLR4: signaling mechanisms in response to LPS and minimally oxidized LDL Br. J. Pharmacol. 167 2012 990 999
74. P.J. Coopman et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells Nature 406 2000 742 747
75. P.J. Coopman, and S.C. Mueller The Syk tyrosine kinase: a new negative regulator in tumor growth and progression Cancer Lett. 241 2006 159 173
76. M. Moroni et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells Cancer Res. 64 2004 7346 7354
77. Y. Yuan et al. Hypermethylation leads to silencing of the SYK gene in human breast cancer Cancer Res. 61 2001 5558 5561
78. J. Blancato et al. SYK allelic loss and the role of Syk-regulated genes in breast cancer survival PLoS ONE 9 2014 e87610
79. O. Bailet et al. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest Cancer Res. 69 2009 2748 2756
80. Y. Yuan et al. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma Clin. Cancer Res. 12 2006 6687 6695
81. J. Hong et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma J. Clin. Invest. 122 2012 2165 2175
82. T. Layton et al. Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion Am. J. Pathol. 175 2009 2625 2636
83. A. Rinaldi et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma Br. J. Haematol. 132 2006 303 316
84. L. Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Blood 111 2008 2230 2237
85. A.D. Baudot et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression Oncogene 28 2009 3261 3273
86. M. Buchner et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia Cancer Res. 69 2009 5424 5432
87. R.M. Young et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target Blood 113 2009 2508 2516
88. +) B cell lymphomas J. Biol. Chem. 286 2011 37368 37378
89. R.C. Rickert New insights into pre-BCR and BCR signalling with relevance to B cell malignancies Nat. Rev. Immunol. 13 2013 578 591
90. J.G. Monroe ITAM-mediated tonic signalling through pre-BCR and BCR complexes Nat. Rev. Immunol. 6 2006 283 294
91. C.K. Hahn et al. Proteomic and genetic approaches identify Syk as an AML target Cancer Cell 16 2009 281 294
92. A. Feldman et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas Leukemia 22 2008 1139 1143
93. P.G. Miller et al. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling Cancer Cell 24 2013 45 58
94. J.W. Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2010 2578 2585
95. S.E.M. Herman et al. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia Leukemia 27 2013 1769 1773
96. A. Singh et al. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival Cancer Cell 15 2009 489 500
97. X. Chen et al. A novel retinoblastoma therapy from genomic and epigenetic analyses Nature 481 2012 329 334
98. E. Katz et al. MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture J. Exp. Med. 201 2005 431 439
99. P. Prinos et al. Alternative splicing of SYK regulates mitosis and cell survival Nat. Struct. Mol. Biol. 18 2011 673 679
100. J. Carnevale et al. SYK regulates mTOR signaling in AML Leukemia 27 2013 2118 2128
101. L. Leseux et al. Syk-dependent mTOR activation in follicular lymphoma cells Blood 108 2006 4156 4162
102. S. Gobessi et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells Leukemia 23 2009 686 697
103. Q. Ding et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization Mol. Cell. Biol. 27 2007 40006 44017
104. L. Chen et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas Cancer Cell 23 2013 826 838
105. A. Puissant et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia Cancer Cell 25 2014 226 242
106. M.I. Davis et al. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
107. R.T. Burke et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor Oncotarget 5 2014 908 915
108. S.E. Spurgeon et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia J. Pharmacol. Exp. Ther. 344 2013 378 387